SAN DIEGO, CA - March 12, 2025 ( NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY) today released the following note authored by its CEO, Jim Joyce.

“The effectiveness of the COVID vaccines can vary depending on which variants are targeted in the vaccine, which variants are circulating, and host factors,” said Shirin A. Mazumder, MD, and ...

Under normal circumstances, the study of health problems after COVID vaccinations posted online on Feb. 25 might not have ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

This research investigated averted hospitalizations in Oregon and Washington, which had greater than 75% uptake of at least 1 ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

Freshfields represented Moderna, while Taylor Wessing advised BioNTech and Munich IP-firm df-mp was counsel to Pfizer.

New research suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development, an ...

There is a word we should never have to utter during the next pandemic: “unprecedented”. That description was used so often, ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...